to study search History

CONKO-005:Adjuvant Therapy in R0-resected Pancreatic Cancer Patients with Gemcitabine plus Erlotinib vs. Gemcitabine over 24 Weeks - a Prospective, Randomized Phase III Study

Organizational Data

DRKS-ID:
DRKS00000247
Recruitment Status:
Recruiting complete, study continuing
Date of registration in DRKS:
2010-03-04
Last update in DRKS:
2015-09-28
Registration type:
Retrospective

Acronym/abbreviation of the study

CONKO-005

URL of the study

http://www.tumorcenter.de

Brief summary in lay language

Pancreatic cancer is a particularly aggressive tumor with a poor prognosis and surgical resection is the only approach with the possibility of curation. For women it is the 4th and for men the 5th cause of tumor-related death. In addition, there is a recurrence rate of approximately 80% within 5 years. In case of a resectable tumor the 5-year survival rates vary in between 15 - 25% and depend on the result of the resection. Recent findings from our study group (Oettle 2007) showed that those patients who received postoperative chemotherapy with the gemcitabine had a significantly lower risk of recurrence than those without adjuvant chemotherapy. Even patients with complete (R0) resection have a poor median survival of approximately 18 months. The CONKO-005 trial will straightly target these R0-resected patients. It has been repeatedly shown that up to 90% of pancreatic cancers overexpress EGFR. For this reason the inhibition of EGFR with "small molecules " like erlotinib might be o special interest. CONKO 005 trial evaluates the combination of gemcitabin and the selective EGFR-tyrosine kinase inhibitor erlotinib in the adjuvant setting. It might help to find out if this treatment is able to further reduce the risk of tumor recurrence by destroying intraoperative remaine or disseminated tumor cells.

Brief summary in scientific language

Erlotinib is an inhibitor of tyrosine kinase epidermal growth factor receptor (EGFR, HER-1). HER1/EGFR is expressed on the surface of normal cells but also by tumor cells. The anti-tumor activity of erlotinib is based on the inhibition of intracellular tyrosine kinase region of HER1, thus preventing the intercellular signal transduction. In preclinical models, inhibition of HER1 / EGFR tyrosinkinase effects the arrest of growth and / or death of the cell. Preclinical data show an additive effect with cytotoxic drugs such as cisplatin, doxorubicin, or paclitaxel. In these combination studies no side effects were shown. For erlotinib are also data available from several phase I, II and III trials. Since January 2007 erlotinib has been admitted to a dose of 100 mg / day p.o. in combination with gemcitabine in the first-line therapy of metastatic pancreatic cancer in Europe . The admission is based on data from a randomized phase III trail with 569 patients, which had demonstrated a significant benefit in overall survival with this combination compared to gemcitabine alone (p= 0.038). Futhermore in this study the combination of erlotinib and gemcitabine was well tolerated (Moore et al. 2007).

Health condition or problem studied

ICD10:
C25 - Malignant neoplasm of pancreas
Healthy volunteers:
No Entry

Interventions, Observational Groups

Arm 1:
Arm A: Erlotinib 100 mg p.o. daily plus Gemcitabin 1000 mg/m² i.v. day 1, 8, 15. repetition day 29 Duration: 6 cycles (24 weeks)
Arm 2:
Arm B: Gemcitabin 1000 mg/m² i.v. day 1, 8, 15. repetition day 29

Endpoints

Primary outcome:
Relaps-free survival (RFS)
Secondary outcome:
Overall survival, Toxicity

Study Design

Purpose:
Treatment
Allocation:
Randomized controlled study
Control:
  • Active control (effective treatment of control group)
Phase:
III
Study type:
Interventional
Mechanism of allocation concealment:
No Entry
Blinding:
No
Assignment:
Parallel
Sequence generation:
No Entry
Who is blinded:
No Entry

Recruitment

Recruitment Status:
Recruiting complete, study continuing
Reason if recruiting stopped or withdrawn:
No Entry

Recruitment Locations

Recruitment countries:
  • Germany
Number of study centers:
Multicenter study
Recruitment location(s):
No Entry

Recruitment period and number of participants

Planned study start date:
No Entry
Actual study start date:
2008-04-15
Planned study completion date:
No Entry
Actual Study Completion Date:
No Entry
Target Sample Size:
450
Final Sample Size:
450

Inclusion Criteria

Sex:
All
Minimum Age:
18 Years
Maximum Age:
no maximum age
Additional Inclusion Criteria:
Histological confirmed diagnosis of an adenocarcinoma of the pancreas, Standardised surgery for tumor resection, e. g. partial pancreatoduodenectomy (Kausch-Whipple), pylorus-sparing partial pancreatoduodenectomy (PPPD), pancreas leftresection. Result of resection: R0, No previous neoadjuvant therapy (chemotherapy or radiation), Performance-Status according to Karnofsky-Scale > 60 %, Patient compliance and geographical situation allowing an adequate follow up, especially the willingness to visit the same center regulary for at least 2 years after surgery, Sufficient bone marrow capacity: WBC > 3.5 × 109 /l, platelets > 100 x 109/l, haemoglobin > 8 g/dl, Written informed consent of the patient prioral any precedure in connection with the study, Male and female patients with an age of at least 18 years, Initiation of the adjuvant therapy as soon as possible postoperative. Soonest 2 weeks after resection but not before completion of the wound healing at latest in between 8 weeks after resection.

Exclusion Criteria

Seriouses systemic disease (with life expectance < 6 months) according to estimation of the investigator, active infection > Grad 2 NCI-CTCAE v3.0, Known HIV infection, Serious systemic disease: Uncontrolled hypertension, ingestive heart failure NYHA III - IV, symptomatic coronary heart disease, uncontrolled cardial arrhythmia > grade II, peripher arterial disease > stage IIb, International Normalized Ratio (INR) > 1.5, prolongation of the activated partial prothrombin time (aPTT) > 1.5 x UNL (upper normal limit), transaminases > 3x UNL, Postoperative measurable tumorlesion, Pregnant or breast-feeding women. Women of child-bearing potential must have an negative pregnancy test performed 7 days prior to start of the treatment, Sexually active males or females with child-bearing potential unwilling to practice sufficient contraception during the study and for 3 months after end of the study medication., Known allergical reactions against the study drugs or the substances included therein, Patients undergoing dialysis, Interstitial pneumonia or symptomatic fibrosis of the lung, Need of immunosuppressive therapy (e. g. transplantation), Severe non-healing wounds, ulcers or bone fracturs, Participation in another experimental clinical trial within 4 weeks prior to entry into the study, Previous or ongoing narcotic drug, medication- or alcohol abuse, Patients which are not able to take in oral drugs, need parenteral nutrition,are known to have an insufficient gastrointestinal resorption or suffer from acute stomac ulcer, Other primary malignancy in the patient's history (except for successfully treated basalioma or carcinoma in situ of the cervix uteri)

Addresses

Primary Sponsor

Charité-Universitätsmedizin Berlin
Augustenburger Platz 1
13353 Berlin
Germany
Telephone:
No Entry
Fax:
No Entry
Contact per E-Mail
URL:
http://www.charite.de
Investigator Sponsored/Initiated Trial (IST/IIT):
Yes

Contact for Scientific Queries

Charité - Universitätsmedizin Berlin CharitéCentrum für Tumormedizin Medizinische Klinik mit Schwerpunkt Hämatologie/ Onkologie
Dr. med. Marianne Sinn
Augustenburger Platz 1
13353 Berlin
Germany
Telephone:
+49 30 450 553 222
Fax:
+49 30 450 553 959
Contact per E-Mail
URL:
No Entry

Contact for Public Queries

Studiensekretariat Charité - Universitätsmedizin Berlin CharitéCentrum für Tumormedizin Medizinische Klinik m. S. Hämatologie und Onkologie
Dr. Marianne Sinn
Auustenburger Platz 1
13353 Berlin
Germany
Telephone:
(030) 450-553 222
Fax:
(030) 450-553 959
Contact per E-Mail
URL:
No Entry

Sources of Monetary or Material Support

Commercial (pharmaceutical industry, medical engineering industry, etc.)

Roche Pharma
Emil-Barell-Strasse 1/ Postfach 1270
79630 Grenzach-Wyhlen
Germany
Telephone:
No Entry
Fax:
No Entry
Contact per E-Mail
URL:
http://www.roche.de

Ethics Committee

Address Ethics Committee

Ethik-Kommission des Landes Berlin
Fehrbelliner Platz 1
10707 Berlin
Germany
Telephone:
+49-30-902291220
Fax:
+49-30-90283383
Contact per E-Mail
URL:
No Entry

Vote of leading Ethics Committee

Date of ethics committee application:
2007-09-11
Ethics committee number:
ZS EK 11 521/07
Vote of the Ethics Committee:
Approved
Date of the vote:
2007-12-17

Further identification numbers

Other primary registry ID:
No Entry
EudraCT Number:
2007-003813-15
Other secondary IDs:
4033532 - bfarm-nr
UTN (Universal Trial Number):
U1111-1114-0833
EUDAMED Number:
No Entry

IPD - Individual Participant Data

Do you plan to make participant-related data (IPD) available to other researchers in an anonymized form?:
No Entry
IPD Sharing Plan:
No Entry

Study protocol and other study documents

Study protocols:
No Entry
Study abstract:
No Entry
Other study documents:
No Entry
Background literature:
No Entry
Related DRKS studies:
No Entry

Publication of study results

Planned publication:
No Entry
Publikationen/Studienergebnisse:
No Entry
Date of first publication of study results:
No Entry
DRKS entry published for the first time with results:
No Entry

Basic reporting

Basic Reporting / Results tables:
No Entry
Brief summary of results:
No Entry